BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced new data providing preclinical proof-of-principle in breast, colorectal and pancreatic cancers for PEG-SN38, a pegylated form of SN38 which is the active moiety of Camptosar®. The data was presented at the 18th EORTC-NCI-AACR (European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research) annual meeting being hosted in Prague, Czech Republic November 7-10, 2006.
